Literature DB >> 27185477

In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.

P Toulon1,2, Y Eloit2, M Smahi3, C Sigaud2, D Jambou2, F Fischer2, A Appert-Flory2.   

Abstract

INTRODUCTION: Activated partial thromboplastin time (aPTT) is a routine clotting assay that is widely used to globally screen for coagulation abnormalities. It is commonly admitted that a prolonged test result, may trigger the need for specific assays to be performed, particularly factor measurement. However, the sensitivity of aPTT reagents to deficiencies of clotting factors varies.
METHODS: We evaluated, according to the recommendation of the CLSI H47-A2 guideline, the responsiveness to single factor levels of five aPTT reagents by using factor-deficient plasmas spiked with a calibration plasma to produce individual factor activities ranging from <1 to ~100 Unit (U)/dL. Test results were expressed as the sample-to-control ratio, the latter was defined as the clotting time obtained in the calibration plasma containing ~100 U/dL factor activity. The factor activity producing a prolongation of aPTT above the upper limit of its specific normal range (in ratio) was assigned as the factor responsiveness in U/dL to that reagent.
RESULTS: Responsiveness ranged from 34 to 47 U/dL to FVIII: C, from 18 to 57 U/dL to FIX, from 38 to 52 U/dL to FXI, from 29 to 50 U/dL to FXII, from 40 and 59 U/dL to FV, from 7.5 to 49 U/dL to FX, and from 9.1 to 10.5 U/dL to FII.
CONCLUSIONS: These results suggest that the sensitivity of the tested aPTT reagents to single factor deficiency is highly variable. Moreover, for one given aPTT reagent, its sensitivity was very different depending on the deficient factor. This must be considered when analyzing clinical materials.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Factor deficiency; activated partial thromboplastin time; reagents; responsiveness; sensitivity

Mesh:

Substances:

Year:  2016        PMID: 27185477     DOI: 10.1111/ijlh.12499

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  6 in total

1.  Molecular Genetic Diagnosis of the Inherited Bleeding Disorders: Are We Close to the Perfect Test?

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-06       Impact factor: 0.900

2.  Cryptogenic oozers and bruisers.

Authors:  Kristi J Smock; Karen A Moser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Factor XI as a target for preventing venous thromboembolism.

Authors:  David Gailani
Journal:  J Thromb Haemost       Date:  2022-01-12       Impact factor: 16.036

4.  Establishing a reference range for thromboelastograph parameters in the neonatal period.

Authors:  Qin Liu; Chunfen Xu; Xin Chen; Jia Wang; Zhunhui Ke; Hongbing Hu
Journal:  Int J Lab Hematol       Date:  2019-05-07       Impact factor: 2.877

Review 5.  Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.

Authors:  Richard A Marlar; Karin Strandberg; Midori Shima; Dorothy M Adcock
Journal:  Eur J Haematol       Date:  2019-11-13       Impact factor: 2.997

6.  Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.

Authors:  Iris van Moort; Piet Meijer; Debby Priem-Visser; Adriaan J van Gammeren; Nathalie C V Péquériaux; Frank W G Leebeek; Marjon H Cnossen; Moniek P M de Maat
Journal:  Haemophilia       Date:  2018-11-29       Impact factor: 4.287

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.